Top

Published in:

Open Access 01-04-2006 | Research article

B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome

Authors: Marc Ittah, Corinne Miceli-Richard, Jacques- Eric Gottenberg, Frédéric Lavie, Thierry Lazure, Nathalie Ba, Jérémie Sellam, Christine Lepajolec, Xavier Mariette

Published in: Arthritis Research & Therapy | Issue 2/2006

Abstract

B cell-activating factor (BAFF) has a key role in promoting B-lymphocyte activation and survival in primary Sjögren's syndrome (pSS). The cellular origin of BAFF overexpression in salivary glands of patients with pSS is not fully known. We investigated whether salivary gland epithelial cells (SGECs), the main targets of autoimmunity in pSS, could produce and express BAFF. We used quantitative RT-PCR, ELISA and immunocytochemistry in cultured SGECs from eight patients with pSS and eight controls on treatment with IL-10, tumor necrosis factor α (TNF-α), IFN-α and IFN-γ. At baseline, BAFF expression in SGECs was low in pSS patients and in controls. Treatment with IFN-α, IFN-γ and TNF-α + IFN-γ increased the level of BAFF mRNA in pSS patients (the mean increases were 27-fold, 25-fold and 62-fold, respectively) and in controls (mean increases 19.1-fold, 26.7-fold and 17.7-fold, respectively), with no significant difference between patients and controls. However, in comparison with that at baseline, stimulation with IFN-α significantly increased the level of BAFF mRNA in SGECs of pSS patients (p = 0.03) but not in controls (p = 0.2), which suggests that SGECs of patients with pSS are particularly susceptible to expressing BAFF under IFN-α stimulation. Secretion of BAFF protein, undetectable at baseline, was significantly increased after IFN-α and IFN-γ stimulation both in pSS patients (40.8 ± 12.5 (± SEM) and 47.4 ± 18.7 pg/ml, respectively) and controls (24.9 ± 8.0 and 9.0 ± 3.9 pg/ml, respectively), with no significant difference between pSS and controls. Immunocytochemistry confirmed the induction of cytoplasmic BAFF expression after stimulation with IFN-α and IFN-γ. This study confirms the importance of resident cells of target organs in inducing or perpetuating autoimmunity. Demonstrating the capacity of SGECs to express and secrete BAFF after IFN stimulation adds further information to the pivotal role of these epithelial cells in the pathogenesis of pSS, possibly after stimulation by innate immunity. Our results suggest that an anti-BAFF therapeutic approach could be particularly interesting in pSS.

Available only for authorised users

Jonsson R, Gordon TP, Konttinen YT: Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sjogren's syndrome. Curr Rheumatol Rep. 2003, 5: 311-316.CrossRefPubMed

Royer B, Cazals-Hatem D, Sibilia J, Agbalika F, Cayuela JM, Soussi T, Maloisel F, Clauvel JP, Brouet JC, Mariette X: Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997, 90: 766-775.PubMed

Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM: Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum. 1999, 42: 1765-1772. 10.1002/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V.CrossRefPubMed

Martin T, Weber JC, Levallois H, Labouret N, Soley A, Koenig S, Korganow AS, Pasquali JL: Salivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum. 2000, 43: 908-916. 10.1002/1529-0131(200004)43:4<908::AID-ANR24>3.0.CO;2-K.CrossRefPubMed

Gasparotto D, De Vita S, De Re V, Marzotto A, De Marchi G, Scott CA, Gloghini A, Ferraccioli G, Boiocchi M: Extrasalivary lymphoma development in Sjogren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum. 2003, 48: 3181-3186. 10.1002/art.11286.CrossRefPubMed

Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT: Lymphoma and other malignancies in primary Sjogren's syndrome. A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2005.

Hansen A, Odendahl M, Reiter K, Jacobi AM, Feist E, Scholze J, Burmester GR, Lipsky PE, Dorner T: Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 2002, 46: 2160-2171. 10.1002/art.10445.CrossRefPubMed

Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K: Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome. J Clin Immunol. 2005, 25: 189-201. 10.1007/s10875-005-4091-5.CrossRefPubMed

Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, et al: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999, 285: 260-263. 10.1126/science.285.5425.260.CrossRefPubMed

10.

Mukhopadhyay A, Ni J, Zhai Y, Yu GL, Aggarwal BB: Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-κB, and c-Jun NH2-terminal kinase. J Biol Chem. 1999, 274: 15978-15981. 10.1074/jbc.274.23.15978.CrossRefPubMed

11.

Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, et al: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999, 189: 1747-1756. 10.1084/jem.189.11.1747.PubMedCentralCrossRefPubMed

12.

Shu HB, Hu WH, Johnson H: TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol. 1999, 65: 680-683.PubMed

13.

Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999, 190: 1697-1710. 10.1084/jem.190.11.1697.PubMedCentralCrossRefPubMed

14.

Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E, Scott ML: An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001, 293: 2111-2114. 10.1126/science.1061964.CrossRefPubMed

15.

O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ: BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004, 199: 91-98. 10.1084/jem.20031330.PubMedCentralCrossRefPubMed

16.

Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S: Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000, 192: 953-964. 10.1084/jem.192.7.953.PubMedCentralCrossRefPubMed

17.

Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002, 3: 822-829. 10.1038/ni829.PubMedCentralCrossRefPubMed

18.

Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, Cyster JG: Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity. 2004, 20: 441-453. 10.1016/S1074-7613(04)00079-2.CrossRefPubMed

19.

Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, Brink R: Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004, 20: 785-798. 10.1016/j.immuni.2004.05.010.CrossRefPubMed

20.

Cheema GS, Roschke V, Hilbert DM, Stohl W: Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001, 44: 1313-1319. 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S.CrossRefPubMed

21.

Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, Migone TS, Hilbert DM, Stohl W: Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 2003, 48: 982-992. 10.1002/art.10860.CrossRefPubMed

22.

Yamada T, Zhang K, Yamada A, Zhu D, Saxon A: B lymphocyte stimulator activates p38 mitogen-activated protein kinase in human Ig class switch recombination. Am J Respir Cell Mol Biol. 2005, 32: 388-394. 10.1165/rcmb.2004-0317OC.CrossRefPubMed

23.

Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, Roschke V, Wu Y, Baker KP, Hilbert DM: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003, 48: 3475-3486. 10.1002/art.11354.CrossRefPubMed

24.

Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, et al: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest. 2002, 109: 59-68. 10.1172/JCI200214121.PubMedCentralCrossRefPubMed

25.

Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R: The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis. 2003, 62: 168-171. 10.1136/ard.62.2.168.PubMedCentralCrossRefPubMed

26.

Szodoray P, Jellestad S, Alex P, Zhou T, Wilson PC, Centola M, Brun JG, Jonsson R: Programmed cell death of peripheral blood B cells determined by laser scanning cytometry in Sjogren's syndrome with a special emphasis on BAFF. J Clin Immunol. 2004, 24: 600-611. 10.1007/s10875-004-6240-7.CrossRefPubMed

27.

Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P: BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci. 2005, 1050: 34-39. 10.1196/annals.1313.004.CrossRefPubMed

28.

Gottenberg JE, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly RP, Sibilia J, Mariette X: Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. Ann Rheum Dis. 2005, 64: 1050-1055. 10.1136/ard.2004.030643.PubMedCentralCrossRefPubMed

29.

Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X: Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol. 2004, 202: 496-502. 10.1002/path.1533.CrossRefPubMed

30.

Szodoray P, Jellestad S, Teague MO, Jonsson R: Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjogren's syndrome. Lab Invest. 2003, 83: 357-365. 10.1097/01.LAB.0000101703.80133.99.CrossRefPubMed

31.

Gottenberg J, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, et al: Activation of interferon pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci USA. 2006.

32.

Ng LG, Mackay CR, Mackay F: The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol. 2005, 42: 763-772. 10.1016/j.molimm.2004.06.041.CrossRefPubMed

33.

Kapsogeorgou E, Manoussakis MN: The central role of epithelial cells in Sjogren's syndrome or autoimmune epithelitis. Autoimmun Rev. 2004, 3 (Suppl 1): S61-S63.PubMed

34.

Manoussakis MN, Moutsopoulos HM: Sjogren's syndrome: autoimmune epithelitis. Baillieres Best Pract Res Clin Rheumatol. 2000, 14: 73-95. 10.1053/berh.1999.0078.CrossRefPubMed

35.

James JA, Harley JB, Scofield RH: Role of viruses in systemic lupus erythematosus and Sjogren syndrome. Curr Opin Rheumatol. 2001, 13: 370-376. 10.1097/00002281-200109000-00005.CrossRefPubMed

36.

Matsumura R, Umemiya K, Goto T, Nakazawa T, Kagami M, Tomioka H, Tanabe E, Sugiyama T, Sueishi M: Glandular and extraglandular expression of costimulatory molecules in patients with Sjogren's syndrome. Ann Rheum Dis. 2001, 60: 473-482. 10.1136/ard.60.5.473.PubMedCentralCrossRefPubMed

37.

Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN: Functional expression of a costimulatory B7.2 (CD86) protein on human salivary gland epithelial cells that interacts with the CD28 receptor, but has reduced binding to CTLA4. J Immunol. 2001, 166: 3107-3113.CrossRefPubMed

38.

Manoussakis MN, Dimitriou ID, Kapsogeorgou EK, Xanthou G, Paikos S, Polihronis M, Moutsopoulos HM: Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjogren's syndrome. Arthritis Rheum. 1999, 42: 229-239. 10.1002/1529-0131(199902)42:2<229::AID-ANR4>3.0.CO;2-X.CrossRefPubMed

39.

Xanthou G, Polihronis M, Tzioufas AG, Paikos S, Sideras P, Moutsopoulos HM: 'Lymphoid' chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjogren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum. 2001, 44: 408-418. 10.1002/1529-0131(200102)44:2<408::AID-ANR60>3.0.CO;2-0.CrossRefPubMed

40.

Tsunawaki S, Nakamura S, Ohyama Y, Sasaki M, Ikebe-Hiroki A, Hiraki A, Kadena T, Kawamura E, Kumamaru W, Shinohara M, et al: Possible function of salivary gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjogren's syndrome. J Rheumatol. 2002, 29: 1884-1896.PubMed

41.

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, et al: Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002, 61: 554-558. 10.1136/ard.61.6.554.PubMedCentralCrossRefPubMed

42.

Dimitriou ID, Kapsogeorgou EK, Abu-Helu RF, Moutsopoulos HM, Manoussakis MN: Establishment of a convenient system for the long-term culture and study of non-neoplastic human salivary gland epithelial cells. Eur J Oral Sci. 2002, 110: 21-30. 10.1034/j.1600-0722.2002.00152.x.CrossRefPubMed

43.

Regauer S, Beham A, Mannweiler S: CK7 expression in carcinomas of the Waldeyer's ring area. Hum Pathol. 2000, 31: 1096-1101. 10.1053/hupa.2000.6279.CrossRefPubMed

44.

Mackay F, Schneider P, Rennert P, Browning J: BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003, 21: 231-264. 10.1146/annurev.immunol.21.120601.141152.CrossRefPubMed

45.

Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, Kipps TJ: Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol. 2005, 174: 864-870.CrossRefPubMed

46.

Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, Kalled SL, Hess DM, Serafini B, Aloisi F, et al: BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005, 201: 195-200. 10.1084/jem.20041674.PubMedCentralCrossRefPubMed

47.

Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, Sosnovtseva S, Carrell JA, Feng P, Giri JG, Hilbert DM: Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001, 97: 198-204. 10.1182/blood.V97.1.198.CrossRefPubMed

48.

Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puechal X, Pennec Y, Sauvezie B, et al: Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum. 2004, 50: 1270-1276. 10.1002/art.20146.CrossRefPubMed

49.

Alvaro-Gracia JM, Yu C, Zvaifler NJ, Firestein GS: Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on fibroblast-like synoviocytes: paradoxical induction of IFN-gamma and TNF-alpha receptor expression. J Clin Immunol. 1993, 13: 212-218. 10.1007/BF00919974.CrossRefPubMed

50.

Pascual V, Banchereau J, Palucka AK: The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol. 2003, 15: 548-556. 10.1097/00002281-200309000-00005.CrossRefPubMed

51.

Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, Alm GV, Ronnblom L: Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 2005, 52: 1185-1195. 10.1002/art.20998.CrossRefPubMed

52.

Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI: Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum. 2005, 52: 1534-1544. 10.1002/art.21006.CrossRefPubMed

53.

Triantafyllopoulou A, Tapinos N, Moutsopoulos HM: Evidence for coxsackievirus infection in primary Sjogren's syndrome. Arthritis Rheum. 2004, 50: 2897-2902. 10.1002/art.20463.CrossRefPubMed

54.

Mariette X, Gozlan J, Clerc D, Bisson M, Morinet F: Detection of Epstein-Barr virus DNA by in situ hybridization and polymerase chain reaction in salivary gland biopsy specimens from patients with Sjogren's syndrome. Am J Med. 1991, 90: 286-294.CrossRefPubMed

55.

Mariette X, Agbalika F, Daniel MT, Bisson M, Lagrange P, Brouet JC, Morinet F: Detection of human T lymphotropic virus type I tax gene in salivary gland epithelium from two patients with Sjogren's syndrome. Arthritis Rheum. 1993, 36: 1423-1428.CrossRefPubMed

56.

Mariette X, Zerbib M, Jaccard A, Schenmetzler C, Danon F, Clauvel JP: Hepatitis C virus and Sjogren's syndrome. Arthritis Rheum. 1993, 36: 280-281.CrossRefPubMed

57.

Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF, et al: Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood. 2004, 104: 2247-2253. 10.1182/blood-2004-02-0762.CrossRefPubMed

58.

Delaleu N, Jonsson R, Koller MM: Sjogren's syndrome. Eur J Oral Sci. 2005, 113: 101-113. 10.1111/j.1600-0722.2004.00183.x.CrossRefPubMed

Title: B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome
Authors: Marc Ittah
Corinne Miceli-Richard
Jacques- Eric Gottenberg
Frédéric Lavie
Thierry Lazure
Nathalie Ba
Jérémie Sellam
Christine Lepajolec
Xavier Mariette
Publication date: 01-04-2006
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 2/2006
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar1912

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2006

The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells

Association between microscopic brain damage as indicated by magnetization transfer imaging and anticardiolipin antibodies in neuropsychiatric lupus

Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3receptor activation in thioglycollate-induced peritonitis

Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs

Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis

Magnetic resonance imaging in psoriatic arthritis: a review of the literature

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials